Selected article for: "relative virus and RT PCR"
Author: Zapor, Michael
Title: Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical Specimens from COVID-19 Patients
  • Cord-id: jyd2v4ux
  • Document date: 2020_12_3
    • ID: jyd2v4ux
    Snippet: The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) that emerged in December 2019 as the causative agent of Coronavirus 2019 (COVID-19) and was declared a pandemic by the World Health Organization in March 2020 has several distinctive features, including extensive multiorgan involvement with a robust systemic inflammatory response, significant associated morbidity and mortality, and prolonged persistence of viral RNA in the clinical specimens of infected individuals as detected by Rev
    Document: The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) that emerged in December 2019 as the causative agent of Coronavirus 2019 (COVID-19) and was declared a pandemic by the World Health Organization in March 2020 has several distinctive features, including extensive multiorgan involvement with a robust systemic inflammatory response, significant associated morbidity and mortality, and prolonged persistence of viral RNA in the clinical specimens of infected individuals as detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR) amplification. This review begins with an overview of SARS-CoV-2 morphology and replication and summarizes what is known to date about the detection of the virus in nasal, oropharyngeal, and fecal specimens of patients who have recovered from COVID-19, with a focus on the factors thought to contribute to prolonged detection. This review also provides a discussion on the infective potential of this material from asymptomatic, pre-symptomatic, and convalescing individuals, to include a discussion of the relative persistence and infectious potential of virus in clinical specimens recovered from pediatric COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and acute sars respiratory syndrome virus: 1, 2, 3, 4
    • active research and acute sars respiratory syndrome virus: 1
    • active research and additional study: 1
    • active research and local prevalence: 1
    • active research and long term sequelae: 1
    • acute kidney injury and additional study: 1, 2, 3
    • acute kidney injury and long term sequelae: 1, 2, 3, 4
    • acute kidney injury and lymph node: 1, 2
    • acute kidney injury and lymphoblastic leukemia: 1, 2
    • acute kidney injury and lymphocyte infiltration: 1, 2
    • acute lymphoblastic leukemia and lymph node: 1, 2, 3
    • acute lymphoblastic leukemia and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
    • acute sars respiratory syndrome virus and additional study: 1, 2, 3
    • acute sars respiratory syndrome virus and local prevalence: 1